ERCC1 and gastric cancer: Conflicting clinical trial reports exist regarding the role of ERCC1 expression in predicting cisplatin treatment on gastric cancer: some claimed that patients benefit more from low ERCC1 expression [28–32], some stated the opposite [33–35], while still others found no connection at all [36].